{"id":474390,"date":"2020-03-17T10:24:02","date_gmt":"2020-03-17T10:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474390"},"modified":"2020-03-17T10:24:02","modified_gmt":"2020-03-17T10:24:02","slug":"openangle-glaucoma-oag-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/openangle-glaucoma-oag-market-insights-epidemiology-and-market-forecast-2030_474390.html","title":{"rendered":"Open-angle glaucoma (OAG) Market Insights, Epidemiology, and Market Forecast- 2030"},"content":{"rendered":"
\"Open-angle<\/a><\/div>\n
DelveInsight\u2019s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast – 2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

Albany, NY –<\/strong> DelveInsight launched its new report on Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast—2030<\/a><\/p>\n

DelveInsight’s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast—2030<\/strong> (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n

Some key facts of the report:<\/strong>
1. Approximately 45 million people were affected by Open-angle glaucoma worldwide, and by 2020 this number is expected to increase to 58.5 million.
2. The overall Open-angle glaucoma prevalence in older individuals is 1.86%, owing to the rapidly ageing population.
3. In Europe, an estimated Open-angle glaucoma prevalence to be around 1–3% in persons, 40 years and older.<\/p>\n

Key benefits of the report:<\/strong>
1. Open-angle glaucoma market report covers a descriptive overview and comprehensive insight of the Open-angle glaucoma epidemiology and Open-angle glaucoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Open-angle glaucoma market report provides insights into current and emerging therapies.
3. Open-angle glaucoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Open-angle glaucoma market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Open-angle glaucoma market.<\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/open-angle-glaucoma-market<\/p>\n

Open-angle glaucoma (OAG)<\/strong> is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by open-angle of the anterior iridocorneal chamber, typical optic nerve head changes, progressive loss of peripheral vision (typical visual field changes) followed by central visual field loss (blindness) for which intraocular pressure (IOP) is an important risk factor. <\/p>\n

\"\"<\/p>\n

Key pharma players involved:<\/strong>
1. Ocular Therapeutix
2. Santen Pharmaceutical
3. Laboratorios Sophia
4. Chong Kun Dang Pharmaceutical
5. Nicox Ophthalmics<\/p>\n

Drugs covered:<\/strong>
1. OTX-TP
2. Sepetaprost
3. PRO-122<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/open-angle-glaucoma-market<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction<\/span>
2. Open-Angle Glaucoma Market Overview at a Glance<\/span>
3. Open-Angle Glaucoma Disease Background and Overview<\/span>
4. Open-Angle Glaucoma Epidemiology and Patient Population<\/span>
4.1. Open-Angle Glaucoma Country-Wise Epidemiology<\/span>
4.1.1. United States<\/span>
4.1.2. EU-5<\/span>
4.1.3 Germany<\/span>
4.1.4 France<\/span>
4.1.5. Italy<\/span>
4.1.6. Spain<\/span>
4.1.7. United Kingdom<\/span>
4.1.8. Japan<\/span>
5. Open-Angle Glaucoma Treatments & Medical Practices<\/span>
6. Unmet needs<\/span>
7. Open-Angle Glaucoma Marketed Therapies<\/span>
7.1. Rhopressa: Aerie Pharmaceuticals<\/span>
7.2. Vyzulta: Bausch & Lomb<\/span>
8. Open-Angle Glaucoma Emerging Therapies<\/span>
9. Key Cross Competition<\/span>
9.1. OTX-TP: Ocular Therapeutix<\/span>
9.2. PRO-122: Laboratorios Sophia<\/span>
9.3. Sepetaprost: Santen Pharmaceutical<\/span>
10. Open-Angle Glaucoma Market Size<\/span>
11. 7MM Open-Angle Glaucoma: Country-Wise Market Analysis<\/span>
12. United States Market Size<\/span>
13. Germany Market Size<\/span>
14. France Market Size<\/span>
15. United Kingdom Market Size<\/span>
16. Spain Market Size<\/span>
17. Italy Market Size<\/span>
18. Japan Market Size<\/span>
19. Report Methodology<\/span>
20. DelveInsight Capabilities<\/span>
21. Disclaimer<\/span>
22. About DelveInsight<\/span><\/p>\n

Related reports:<\/strong><\/span><\/p>\n

Open-Angle Glaucoma Pipeline Insight, 2020<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight\u2019s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast – 2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-474390","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=474390"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474390\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=474390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=474390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=474390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}